Opportunities to widen your network and absorb deep business and legal insight.

Maximizing Patent Term & Synchronizing Regulatory Exclusivities for Pharmaceutical/Biotech Inventions in the US, Europe and Japan

10 July 2017


  • Foley & Lardner LLP
    111 Huntington Avenue
    Suite 2600
    Boston, MA


12:45 pm - 1:00 pm: Lunch
1:00 pm - 4:15 pm: Program
4:15 pm - 5:30 pm: Reception

Contact Information

Delia Dai
Leveraging a global patent portfolio to maximize value can be a complicated challenge for pharmaceutical products marketed internationally.

A key concern for many companies is how best to optimize market exclusivity in different commercially relevant territories.

Understanding key differences in the patent term extension laws of the US, Europe and Japan is essential to knowing when a product is eligible for extension and where.

Please join us for a lively discussion that will address topics including:

  • Important differences and similarities between patent term extension regimes in the United States, Europe and Japan (including when combination products and esters/salts are considered “new” enough to be eligible)
  • Strategies for maximizing Patent Term Adjustment for United States patents
  • Aligning patent prosecution strategies with regulatory approval and non-patent regulatory exclusivities (such as NCE exclusivity in the US and supplemental protection certificates (SPCs) in Europe).

Featured Speakers

Due to seating limitations, pre-registration is required. To register, please use either the Register button above, or contact Delia Dai at ddai or 312.832.4506.